OptiNose, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPTN research report →
About the company
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid.
- CEO
- Ramy A. Mahmoud
- IPO
- 2017
- Employees
- 127
- HQ
- Yardley, PA, US
Price Chart
- Market Cap
- $97.22M
- P/E
- -4.53
- P/S
- 1.24
- P/B
- -2.42
- EV/EBITDA
- -118.28
- Div Yield
- 0.00%
- Gross Margin
- 90.76%
- Op Margin
- -20.86%
- Net Margin
- -27.54%
- ROE
- 33.93%
- ROIC
- -17.42%
- Revenue
- $78.23M · 10.20%
- Net Income
- $-21,541,000 · 39.29%
- EPS
- $-2.12 · -562.50%
- Op Income
- $-16,319,000
- FCF YoY
- -114.53%
- 52W High
- $20.02
- 52W Low
- $4.82
- 50D MA
- $8.91
- 200D MA
- $8.83
- Beta
- -0.89
- Avg Volume
- 119.12K
Get TickerSpark's AI analysis on OPTN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 21, 25 | Marino Michael F III | sell | 5,333 |
| May 21, 25 | Marino Michael F III | sell | 9,626 |
| May 21, 25 | Marino Michael F III | sell | 16,752 |
| May 21, 25 | Marino Michael F III | sell | 5,500 |
| May 21, 25 | Marino Michael F III | sell | 12,350 |
| May 21, 25 | Marino Michael F III | sell | 125,204 |
| May 21, 25 | Marino Michael F III | sell | 10,575 |
| May 21, 25 | Marino Michael F III | sell | 5,775 |
| May 21, 25 | Marino Michael F III | sell | 3,056 |
| May 21, 25 | Marino Michael F III | sell | 9,333 |
Our OPTN coverage
Recent articles, reports, and earnings notes.
No research on OPTN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPTN report →Similar companies
Peers in the same neighborhood.